Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Laurus Labs

+33.44% revenue YoY

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, unaudited

Reported revenue (₹ crore, except EPS in ₹/share): 2,206.37

Read summary and comparison caveats

Laurus Labs reported consolidated revenue of ₹2,206.37 crore, up 33.44% year on year and 8.89% from June. Profit attributable to equity holders rose to ₹441.48 crore, compared with ₹194.97 crore a year ago and ₹367.60 crore in June. Total group profit after the share of associates and joint venture was ₹436.19 crore, a different attribution basis.

  • Source: consolidated statement on PDF page 2 and notes on page 5. The statement is already in ₹ crore; no million/lakh conversion is applied. Changes use original amounts before rounding. EPS is reported and not annualised.
  • Year ago is the quarter ended 30 Sep 2025; previous quarter is 30 Jun 2026. Equity holders' PAT of ₹441.48 crore plus non-controlling loss of ₹5.29 crore equals total group PAT of ₹436.19 crore. That total includes ₹0.55 crore share of associate/joint-venture losses; the preceding ₹436.74 crore PAT line is not substituted for owners' profit.
  • Total tax expense was ₹155.08 crore versus ₹75.98 crore a year ago and ₹119.37 crore in June. Deferred-tax credits were ₹7.86 crore, ₹11.93 crore and ₹15.51 crore respectively. Reported PAT is not an adjusted or recurring-profit estimate.
  • The group reports one pharmaceuticals segment. Consolidation includes Laurus Bio at 78.34%, associates and the 49% KRKA Pharma joint venture; standalone results are not mixed into the comparison.
  • The proposed Synthesis/Sriam scheme remains subject to approvals. The company says these consolidated results do not give effect to the proposed merger. Laurus Generics GmbH liquidation remains ongoing through its statutory creditor-objection period; the note describes its net assets and results as not material.
  • The company allotted 455,636 ESOP shares during the half year. Reported EPS uses its applicable share basis. The ₹1 per-share interim dividend approved on 29 Oct is a distribution decision, not an addition to quarterly PAT.
  • No separate exceptional-item line appears in this consolidated statement. No EBITDA or acquisition-adjusted profit is inferred from a press release. Board-outcome, presentation and press-release notices are not counted as separate company results.
  • Selected original-source coverage, not a complete market list. Raw RSS notice time has no timezone suffix.

Checked 29 Oct 2026

Open original filing
Read the complete published results desk